AFMD
- Affimed N.V.
()
Overview
Company Summary
Affimed N.V. (AFMD) is a clinical-stage biopharmaceutical company that specializes in the development of targeted immunotherapies for the treatment of various types of cancer. The company has developed a proprietary technology platform called ROCK� (Redirected Optimized Cell Killing), which enables the engineering of highly specific and potent immune cell engagers (ICE) that can recognize and eliminate cancer cells.
Affimed's immunotherapies are designed to activate and redirect the body's own immune system to selectively target and destroy cancer cells. These therapies are based on bispecific antibodies that bind to both cancer cells and immune cells, bringing them into close proximity and facilitating the destruction of cancer cells.
The company focuses on developing therapies for hematologic cancers, including non-Hodgkin lymphoma, acute lymphoblastic leukemia, and multiple myeloma. Affimed's lead product candidate, AFM13, is being studied in clinical trials for Hodgkin lymphoma and CD30-positive lymphomas.
Affimed is also actively engaged in collaborations with pharmaceutical companies to explore the potential of its ROCK� platform in combination with other immuno-oncology therapies. These partnerships aim to enhance the therapeutic potential and broaden the applicability of Affimed's immunotherapies across a range of cancer indications.
In summary, Affimed N.V. is dedicated to advancing innovative immunotherapies that harness the power of the immune system to target and eliminate cancer cells, ultimately improving the treatment outcomes for patients with various types of cancer.